Immuno-oncology drug market players innovate through strategic collaborations to win

Immuno-Oncology Drugs Market Report 2022 - Opportunities and Strategies - Forecast to 2031

Immuno-Oncology Drugs Market Report 2022 – Opportunities and Strategies – Global Forecast to 2031

The Business Research Company’s Immuno-Oncology Drugs Market – Opportunities and Strategies – Global Forecast to 2031

LONDON, GREATER LONDON, UK, October 24, 2022 / — Product innovations through strategic collaborations are contributing to the growth of immuno-oncology drug market. In January 2021, Boehringer Ingelheim, a German-based pharmaceutical company, collaborated with Enara Bio for an undisclosed amount. This collaboration combines Boehringer Ingelheim’s approach to tackling cancer by uniting leading science with innovative immuno-oncology platforms, such as oncolytic viruses and cancer vaccines, with Enara Bio’s expertise in cancer antigen identification. Enara Bio is a UK-based science company focused on the T cell/cancer-cell interface (the “immune synapse”) to develop novel cancer immunotherapies designed to treat a broad patient population. Therefore, strategic collaborations are expected to drive the growth of the immuno-oncology drug market.

The global immuno-oncology drug market size is expected to grow from $67.88 billion in 2021 to $116.24 billion in 2026 at a rate of 11.4%. The global immuno-oncology drug market share is expected to grow at a CAGR of 10.0% from 2026 and reach $186.92 billion in 2031.

Learn more about the Global Immuno-Oncology Drug Market Report

Drugmakers are investing in developing personalized cancer vaccines, and few have reached the clinical trial stages. Pharmaceutical companies are combining genetic sequencing and precision medicine to create new drug therapies and cancer treatments designed to treat specific patients. DNA vaccines are easy and cost effective to manufacture compared to other neoantigen vaccines. For example, in April 2021, a researcher at the University of Washington School of Medicine showed that personalized cancer vaccines made from DNA can program the immune system to attack malignant tumors, including breast and pancreatic cancers. The findings also showed that a personalized DNA vaccine in conjunction with other immunotherapies can generate a robust immune response capable of shrinking breast cancers in mice.

The major players covered in the global immuno-oncology drug market are F. Hoffmann-La Roche Ltd., Merck & Co., Bristol-Myers Squibb Company, Amgen Inc., Johnson & Johnson.

The TBRC immuno-oncology drug market report is segmented by type into immune checkpoint inhibitors, immune system modulators, other monoclonal antibodies, cancer vaccines, others, by therapeutic application in melanoma, lung cancer, blood cancer , renal cell carcinoma, bladder cancer, other applications, by end users in hospitals, clinics, ambulatory surgical centers, others.

Immuno-oncology drug market 2022 – By type (immune checkpoint inhibitors, immune system modulators, other monoclonal antibodies, cancer vaccines, others), by therapeutic application (melanoma, lung cancer, blood cancer, renal cell carcinoma, bladder cancer , other therapeutic application), By End Users (Hospitals, Clinics, Ambulatory Surgical Centers, Other), And By Region, Opportunities And Strategies: Global Forecast To 2031 is one of a series of new reports from The Business Research Company that provides an overview immuno-oncology drug market overview, forecast immuno-oncology drug Market size and growth for the entire market, immuno-oncology drug market segments, geographies, immuno-oncology drug market trends, immuno-oncology drug market drivers, restraints, income, profiles and market shares of the main competitors.

Request for a sample of the Global Immuno-Oncology Drugs Market report

Not what you were looking for? Here is a list of similar reports from The Business Research Company:

Global Checkpoint Inhibitors Market Report 2022: By Drug (PD-1 Inhibitors, PD-L1 Inhibitors, CTLA-4, Chimeric Antigen Receptor T Cell), By Application (Lung Cancer, Kidney Cancer, Blood Cancer, Bladder Cancer, Melanoma), By End Users (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies): Market Size, Trends and Global Forecast 2022-2026

Global Monoclonal Antibodies (MAbs) Market Report 2022: By Source (Murine, Chimeric, Humanized, Human), By Application (Anticancer, Immunological, Anti-Infectious Monoclonal Antibodies (MAbs), Neuropharmacological, Cardiovascular, and Cerebrovascular), By End-User ( Hospitals, Private Clinics, Research Institute) – Market Size, Trends and Global Forecast 2022-2026

Global Oncology Drugs Market Report 2022 – By Type (Lung Cancer Drugs, Pancreatic Cancer Drugs, Breast Cancer Drugs, Prostate Cancer Drugs, Ovarian Cancer Drugs, Cancer Drugs) Colorectal Cancer, Gastric Cancer Drugs, Kidney Cancer Drugs, Brain Tumor Drugs, Thyroid Cancer Drugs, Skin Cancer Drugs, Bladder Cancer Drugs, Cervical Cancer Drugs, Drugs for blood cancer, Other (Kaposi’s sarcoma, AIDS-related lymphoma, anal cancer, bone cancer, retinoblastoma, testicular cancer, hepatocellular (liver) cancer, mouth cancer, neuroblastoma)), By distribution channel ( hospital pharmacies, retail pharmacies/drug stores), by route of administration (oral, parenteral), by drug classification (prescription drugs) ark, Generic Drugs), By Mode of Purchase (Prescription Drugs, OTC Drugs) Drugs): Market Size, Trends and Global Forecast 2022-2026

On The business research company?
The Business Research Company is a market research and intelligence firm that excels in business, market and consumer research. It has more than 200 investigative professionals in its offices in India, the UK and the US, as well as a network of trained investigators globally. It has specialist consultants in a wide range of industries including manufacturing, health care, financial services and technology.
Read more about us at

Call us now for personal assistance with your purchase:
Europe: +44 207 1930 708
Asia: +91 88972 63534
America: +1 315 623 0293

Take a look at our:
TBRC blog:
World market model:
Health Blog:

Oliver Guirdham
business research company
+44 20 7193 0708
Visit us on social networks:

Leave a Comment